Sign in
CompletedNo phase

Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA

Key facts

Who runs it
Imperial College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
22 people enrolled
Started
25 Sept 2020
Ended
1 Mar 2024
Type of study
Observational, 2 groups
Treatments tested
  • [18F]FPIA PET/MRI
Record updated
2 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Treatment naïve; or
  • SRS+/- combination treated - Patients that have completed the SRS part of a combination regime enabling a 4-8 week post-SRS treatment PET/MRI scan; and
  • That fulfil the following criteria:
  • Age ≥18
  • Target metastases size ≥ 1cm
  • WHO performance status 0 - 2
  • If female, the subject is either post-menopausal (at least 1 year), or surgically sterilized (has had a documented bilateral oophorectomy and/or documented hysterectomy for at least 2 years), or if of childbearing potential, must have a negative urine beta human chorionic gonadotropin (beta-hCG) pregnancy test done prior to tracer administration
  • The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained
  • The subject has a satisfactory medical history as judged by the investigator with no significant co-morbidities
  • The subject's clinical and laboratory tests are within normal limits and/or considered clinically insignificant

Who cannot take part

  • Prior use within 14 days of enrolment or concurrent therapy with any other investigational agent
  • The subject has non-MRI compatible devices (e.g.a pacemaker, an implantable cardioverter-defibrillator (ICD), a nerve stimulator, a cochlear implant or a drug pump) or implanted material (e.g. non-MRI compatible sternal wires, biostimulators, metals or alloys)
  • Any other chronic illness that will or musculoskeletal condition that would not allow comfortable performance of a PET study
  • Unsatisfactory renal function (eGFR<30)
  • The subject is pregnant or lactating

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cerebral metastases represent a significant problem for oncological management. It is estimated that 20-40% of patients with cancer will develop metastatic cancer to the brain during the course of their illness. 18F-fluoropivalate ([18F]FPIA) is a new tracer that images short chain fatty acid (SCFA) uptake in tumours, a key component of fatty acid oxidation.

Read full original descriptionShow less

The aim of this study is to quantify the degree of early step fatty acid oxidation in cerebral metastases as imaged by [18F]FPIA Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI).

The investigators hypothesise that FPIA uptake will be higher in metastases that are treatment naïve compared to those that have undergone treatment, in keeping with viable tumour cells having a high propensity to generate ATP and NADPH via fatty acid oxidation under bioenergetic stress.

The 2 groups in the trial

  • Patients With Radiological Evidence of IMD That Are Treatment Naive.

    Participants with radiological evidence of intracranial metastatic disease (IMD) on standard of care contrast-enhanced magnetic resonance imaging (CE-MRI) that were treatment-naive at the time of enrolment/\[18F\]FPIA PET-mpMRI scanning. Participants enrolled into the study had \[18F\]FPIA positron emission tomography-multiparametric magnetic resonance imaging (PET-mMRI) scan(s) performed at the Invicro, Centre for Imaging Sciences. A single intravenous dose of \[18F\]FPIA (maximum, 370MBq) was administered to the participant followed by a whole brain dynamic PET-MRI scan over 66 minutes.

    Treatment: [18F]FPIA PET/MRI

  • Patients With Radiological Evidence of IMD That Had Completed Stereotactic Radiosurgery.

    Participants with radiological evidence of intracranial metastatic disease (IMD) on standard of care contrast-enhanced magnetic resonance imaging (CE-MRI) that had completed stereotactic radiosurgery (SRS) (+/- combination therapy) within 4-8 weeks of \[18F\]FPIA PET-mMRI. Participants enrolled into the study had \[18F\]FPIA positron emission tomography-multiparametric magnetic resonance imaging (PET-mMRI) scans performed at the Invicro, Centre for Imaging Sciences. A single intravenous dose of \[18F\]FPIA (maximum, 370MBq) was administered to the participant followed by a whole brain dynamic PET-MRI scan over 66 minutes.

    Treatment: [18F]FPIA PET/MRI

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Determining the Magnitude of Early Steps of Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA PET/MRI
Publications
Record updated
2 April 2025